Genetic typing to guide first treatment for advanced triple-negative breast cancer
Treatments studied
Part of Cancer clinical trials.
This study tests a new way to choose treatment for advanced triple-negative breast cancer, based on a special analysis of your tumor. The goal is to find a treatment that works better for your specific cancer type.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your cancer is triple-negative breast cancer that has spread or come back and you haven't had treatment for this stage yet.
- You have at least one tumor that can be measured on scans.
- You are willing to provide a tissue sample (biopsy) for special testing.
- You are generally healthy enough to be treated (ability to care for yourself).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests a treatment for people with triple-negative breast cancer that has come back or spread and has continued to progress despite earlier therapies. It may help by trying a new approach in patients who still have enough health to safely receive more treatment.
This trial tests a new drug called SKB264 against standard chemotherapy options for people with advanced triple-negative breast cancer who have not yet received chemotherapy for their advanced disease. The goal is to see if SKB264 works better than the usual treatments.
This study tests a combination of three drugs—lenvatinib (a targeted therapy that blocks blood vessel growth), sintilimab (an immunotherapy that helps your immune system attack cancer), and nab-paclitaxel (a chemotherapy)—as the first treatment for triple negative breast cancer that has spread. The goal is to see if this combination is safe and effective.
This Phase 2 trial tests a treatment plan for triple-negative breast cancer that has come back or kept progressing after prior immunotherapy (sometimes along with targeted therapy or chemotherapy). It may help by trying to make the cancer more controllable when it has become resistant to earlier treatment.
This study tests a new drug (9MW2821) against standard chemotherapy for people with triple-negative breast cancer that has spread or come back after prior treatments. The new drug is designed to target and destroy cancer cells more precisely, potentially offering better outcomes.
This trial tests whether adding an experimental immunotherapy drug (QL1706) with or without bevacizumab to standard chemotherapy can help people with advanced triple-negative breast cancer that hasn't been treated yet. It aims to improve outcomes for patients who have already had earlier treatment but whose cancer has come back or spread.
Hear when a new Advanced Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.